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Uncovering the SUMOylation and ubiquitylation
crosstalk in human cells using sequential peptide
immunopurification
Fre´de´ric Lamoliatte1,2,*, Francis P. McManus1,*, Ghizlane Maarifi3, Mounira K. Chelbi-Alix3 & Pierre Thibault1,2,4
Crosstalk between the SUMO and ubiquitin pathways has recently been reported. However,
no approach currently exists to determine the interrelationship between these modifications.
Here, we report an optimized immunoaffinity method that permits the study of both protein
ubiquitylation and SUMOylation from a single sample. This method enables the unprece-
dented identification of 10,388 SUMO sites in HEK293 cells. The sequential use of SUMO
and ubiquitin remnant immunoaffinity purification facilitates the dynamic profiling of
SUMOylated and ubiquitylated proteins in HEK293 cells treated with the proteasome inhi-
bitor MG132. Quantitative proteomic analyses reveals crosstalk between substrates that
control protein degradation, and highlights co-regulation of SUMOylation and ubiquitylation
levels on deubiquitinase enzymes and the SUMOylation of proteasome subunits. The
SUMOylation of the proteasome affects its recruitment to promyelocytic leukemia protein
(PML) nuclear bodies, and PML lacking the SUMO interacting motif fails to colocalize
with SUMOylated proteasome further demonstrating that this motif is required for PML
catabolism.
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P
rotein SUMOylation corresponds to the reversible conjuga-
tion of small ubiquitin related modifier (SUMO) on the
side chain amine group of a lysine residue on a target
protein. SUMO plays essential roles in protein translocation,
DNA damage response and cell cycle progression1–6. Like other
ubiquitin-like (UBL) modifiers, SUMOylation involves a cascade
of three enzymes: the E1-activating complex SAE1/SAE2, the
E2-conjugating enzyme UBC9 and one of the several E3 ligases
(such as PIAS superfamily or RANBP2)4,6. SUMO maturation
and deSUMOylation are carried out by Sentrin SUMO specific
proteases (SENP). SUMO was first known to modify its canonical
consensus sequence cKxE/D (where c is an aliphatic residue and
x any amino acid), however numerous studies reported other
consensus sequences such as a phospho-dependent sequence,
reverse consensus and non-consensus regions7–9. In human, three
paralogs of SUMO are expressed ubiquitously (SUMO1, 2 and 3)
in all cells, while SUMO4 is expressed in specific organs (kidney,
lymph node and spleen), and SUMO5 was recently reported
to be expressed in testes and blood cells10. Previous reports
indicated that SUMO can interact with ubiquitin in a synergic
or an antagonist manner1,11–13. Moreover, mixed chains of
SUMO and ubiquitin have been identified in different studies,
although their functions remain unknown14,15.
The identification of endogenous SUMOylation sites by mass
spectrometry (MS) remains a challenge due the highly dynamic
nature of SUMOylation, and the complex MS/MS spectra arising
from the branched SUMO remnant of tryptic peptides.
To overcome these problems, we previously generated a 6xHis-
SUMO3-Q87R/Q88N mutant that facilitates the identification
of SUMOylated peptides by MS16. This mutant releases a five
amino acid SUMO remnant that can be immunoprecipitated
using an antibody to enrich for SUMO-modified peptides17.
Similar approaches such as the SUMO3 T90K mutant18 or
the SUMO2 T91R that conveniently use the comme-
rcially available anti-di-glycine antibody have been previously
developed for the identification of SUMO sites19. Moreover,
SUMO mutants for which all lysine residues are replaced by
arginine residues were used to allow for nickel-nitrilotriacetic acid
(NiNTA) purification after Lys-C digestion20. More recently, the
combination of lysine labelling with the overexpression
of a wild-type (WT) like mutant has been reported21. While
these approaches have been designed to enrich SUMOylated
peptides from complex cell extracts, they cannot be used alone
to uncover the prevalence and significance of crosstalk between
UBL modifiers. To address this limitation, we developed a
combined immunoaffinity enrichment strategy that enables the
identification of UBL-modified proteins and applied this method
to examine crosstalk between SUMOylation and ubiquitylation
in the context of protein degradation. Using this approach, we
found several interplay between SUMO and ubiquitin including
the co-regulation of SUMOylation and Ubiquitylation levels on
deubiquitinase enzymes and the SUMOylation of the proteasome
for its recruitment to promyelocytic leukemia protein (PML)
nuclear bodies (NBs).
Results
Optimization of SUMO peptide immunoaffinity purification.
The strategy to identify SUMOylation sites in human cells
relies on our previously designed SUMO mutant (Fig. 1a). To
improve the method we optimized both the immunopurification
approach and the MS analysis of SUMOylated peptides (Fig. 1b).
Cells stably expressing the 6xHis-SUMO3-Q87R/Q88N mutant
(HEK293-SUMO3m) produce a functional SUMO3 cleavable
by trypsin near its C-terminus. After protein extraction
from whole cells, SUMOylated proteins are enriched on NiNTA
column before their digestion on beads. Desalted and dried
samples are reconstituted in an immunopurification incubation
buffer. Tryptic peptides that contain the SUMO remnants are
enriched using an anti-K-(NQTGG) antibody.
We first developed a high sensitivity MS method on the
Orbitrap Fusion, where the automatic gain control (AGC) is
used to control ion accumulation rather than varying the
injection time. Previous studies have shown that an increased
AGC setting led to higher number of identification and a decrease
in the total number of MS/MS spectra acquired in a single
run18,22. Accordingly, we used a fixed AGC value with
long injection times to reach the target AGC value while
keeping the injection time below 3 s (Supplementary Fig. 1).
We found that an AGC of 5,000 yielded similar number of
identification and score compared with higher AGC values
and significantly reduced the injection time to maximize
MS utilization. We further analysed the benefits of this sensitive
method with biological samples where we obtained 375±24
sites for the developed method (AGC of 5e3 and a 3,000ms
injection time) while garnering only 110±15 site using the
classic method (AGC of 1e5 and a 50ms injection time) for
the MS/MS scans.
To enrich SUMOylated peptides, we previously used an
anti-K-(NQTGG) antibody and performed in solution purifica-
tion with further washing and elution steps on 30 kDa centricon
membranes. This method enabled the enrichment of SUMO
peptides from tryptic digests to a level of B12% (ref. 17).
To improve the recovery yield of SUMO peptides, we cross linked
the antibody to protein A/G magnetic beads, and optimized
the binding conditions including the loading capacity
(Supplementary Fig. 2). The cross-linking of the antibody
to magnetic beads with dimethyl pimelimidate (DMP) prevented
the release of heavy and light chain fragments on low pH elution.
Optimal binding conditions were obtained for 2mg of antibody
per ml of bead volume with a crosslinker concentration of
5mM of DMP. We subsequently determined the optimal
antibody:ligand ratio to deplete the pool of SUMOylated
peptides from a tryptic digest of 2mg of NiNTA purified proteins
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Figure 1 | Optimization of a SUMO remnant immunoaffinity purification
strategy. (a) Protein sequences of the endogenous ubiquitin, endogenous
SUMO3 and SUMO3m. (b) Overview of the remnant immunoaffinity
purification. Cell lysates are subjected to a NiNTA column to enrich
SUMOylated proteins before tryptic digestion. Peptides containing the
SUMO3m remnant are enriched using the anti-K-(NQTGG) antibody.
Subsequent peptides are injected on a Tribrid Fusion. Peptide identification
is performed using MaxQuant.
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from MG132-treated cells. We compared the recoveries of
SUMOylated peptides of the cross-linked antibody approach
with that of our previously published in solution binding
strategy (Supplementary Fig. 3a, Supplementary Data 1). While
both methods gave optimal results for the same antibody:ligand
ratio (1mg of antibody for 2mg of NiNTA protein digest),
the cross-linking approach led to higher peptide recoveries
(568±6 SUMO peptides versus 235±39 SUMO peptides) and
enrichment levels (34.7±0.4% versus 4.5±0.7%) compared
with the in solution purification. We also determined the number
of SUMOylated peptides identified by MS when using the
in solution and the cross-linked immunopurification methods,
and found that the cross-linked antibody approach provided
an 85% overlap of SUMO peptides using the in solution
method, and yielded a 2-fold gain in new identifications
(Supplementary Fig. 3b, Supplementary Data 1). To further
optimize the method, we performed a titration, where we
compared the number of identified SUMOylated peptides
with increasing amount of NiNTA protein digest. Using
a single LC-MS/MS run, the number of identified SUMOylated
peptides reached a plateau for immunopurified samples
exceeding 4mg of NiNTA protein digest, where we obtained
1,046 SUMOylated peptides corresponding to an enrichment
level of 50.7% (Supplementary Fig. 3c, Supplementary Data 1).
We noted that the proportion of non-SUMOylated peptides
increased significantly beyond 4mg of protein digest, possibly
through the displacement of hydrophilic SUMOylated peptides
from the reverse phase pre-column by hydrophobic tryptic
peptides. Closer examination of the immunopurified extract
revealed that SUMOylated peptides are more hydrophilic
with a lower proportion of aromatic and aliphatic residues
compared with their non-modified counterparts (Supplementary
Fig. 4). Lastly, we evaluated different incubation buffers to
improve the recovery and the enrichment level of SUMOylated
peptides (Supplementary Fig. 3d, Supplementary Data 1). We
observed that an incubation buffer containing 0.1% NP40
lead to higher number of identification with an average of
1,277 SUMO peptides and higher enrichment level (81.1%).
However, traces of NP40 were still detected in the LC-MS/MS
analysis, which compromised the identification of SUMOylated
peptides over repeated injections. Accordingly, we opted to
use phosphate buffered saline (PBS) containing 50% glycerol
as the buffer of choice, which led to the identification of
1,118 SUMO peptides with an enrichment level of 62.9%.
We benchmarked our approach by profiling the changes
in protein SUMOylation on treatment of HEK293 cells with
10 mM MG132, a proteasome inhibitor known to affect the
levels of protein ubiquitylation and SUMOylation. We evaluated
the effect of MG132 over an incubation period of 8 h to further
compare the improvement of the present protocol with that
of our previous study17. It is noteworthy that cell viability for
either HEK293 or HEK293-SUMO3m cells remained unaffected
over the course of these experiments. We evaluated the
reproducibility using three biological replicates originating
from different cell cultures with three technical replicates each,
where protein extracts were separated and the workflows
performed in parallel. A total of 1,640 SUMO sites were
identified on 1,983 SUMOylated peptides across all replicates
using 4mg of protein extract per replicate. Among all identified
SUMOylated sites, we found that 72% were shared across the
different biological replicates (Supplementary Fig. 5). Moreover,
reproducible label-free quantification was obtained for all
biological replicates with a Pearson coefficient 40.9.
We also noted that an increasing number of new
peptide identifications were obtained with each additional
replicate (Supplementary Fig. 5). Indeed, we found that a
second and third injection provided a gain of 21 and 7% in
new identification, respectively. We surmised that the stochastic
nature of MS/MS acquisition and the low abundance of SUMO
peptide ions might partly explain this observation. This is
consistent with the gain in identification associated with the
increase in MS2 injection time, suggesting that SUMO peptides
of low abundance required better ion statistics for proper
assignment.
Comprehensive SUMO proteome analysis. As described
previously, a limited number of identification was obtained
from a single LC-MS/MS analysis of immunopurified samples
for an equivalent of 4mg of protein extracts. To increase
SUMO proteome coverage and minimize sample overloading on
the reverse phase pre-column for injections exceeding 4mg of
digest from NiNTA purified proteins, we fractionated the
samples using strong cation exchange (SCX) spin tips before
LC-MS/MS analysis. Two technical replicates were prepared
using 16mg of protein extract from MG132-treated cells,
and SUMOylated peptides were purified as indicated above.
After immunopurification, peptides were separated into 6 SCX
fractions, each replicate corresponding to 8mg of cell
extract (B40 million cells). This approach yielded an unprece-
dented number of identification with 9,816 SUMO sites on
3,405 proteins corresponding to enrichment levels above
70% (Supplementary Data 1 and 2). In contrast, the same
analysis performed using reverse phase LC-MS/MS only yielded
1,170 SUMO sites (Supplementary Fig. 3c). It is noteworthy,
that 2D-LC-MS/MS experiments performed using the in
solution antibody binding protocol previously identified only
954 SUMO sites17. The further enrichment of SUMOylated
peptides observed here is partly explained by the sample
decomplexification which enabled the identification of lower
abundance SUMOylated peptides, and the increased capacity
of the SCX column that facilitates the retention of hydrophilic
SUMOylated peptides that would otherwise be displaced on
the reverse phase trapping column by other tryptic peptides
(Supplementary Fig. 4).
To determine the depth and comprehensiveness of the present
SUMO immunoaffinity enrichment approach, we compared
our data with those of recent large-scale SUMO proteome studies
(Supplementary Fig. 6)17–21,23–28. Among the 6,288 SUMO sites
reported in 11 large-scale studies using different treatments
and cell types, 47% of these sites were identified in our study
while the remainder was detected mostly in single studies29.
We observed that SUMOylated peptides of higher intensity are
most consistently observed across different studies suggesting
that highly abundant SUMOylated peptides are more likely to
be identified when using different cell types and stimuli.
To gain further insights into the nature of SUMO peptides
identified in the present study, we analysed the sequence motifs
of amino acids surrounding the SUMOylated lysine residues
(±6 amino acids) using Motif X (ref. 30), and identified
35 motifs clustered into 10 different groups (Fig. 2a). We
determined that 12% of all the identified sites resided in the
full consensus motif cKxE/D and 13% in the partial consensus
motif xKxE/D. In addition to the previously known consensus
motifs, new motifs emerged in this study, including the
partial aliphatic and aromatic sequences c/jK (14%) as well
as the corresponding inverted sequences Kc/j (13%), where
j represents Phe or Tyr residues. Moreover, another group
of consensus motifs showed characteristics arising from
the canonical consensus and the inverted sequences: DIK and
KLE. Finally, 25% of all the sites were not attributed to a
consensus sequence. To understand the unusually low proportion
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of consensus sequences observed in the 2D-LC experiments,
we mapped the distribution of motifs according to peptide
intensities (Fig. 2b). This distribution revealed that common
consensus motifs such as xKxE/D or E/DxKx are over represented
in high intensity peptides, while other non-consensus motifs
are mainly found in low intensity peptides. This over representa-
tion of consensus motifs for high intensity peptides is in
agreement with the work of Hendriks et al.20, and might
be explained by UBC9 activity. Indeed, UBC9 is constitutively
expressed in cells and is able to SUMOylate consensus sequences
while non-canonical sequences requires E3 ligases for the proper
transfer of SUMO onto their substrates31.
We also identified 125 SUMOylated peptides containing phos-
phorylated residues (localization confidence 40.75) on serine
(81 sites), threonine (9 sites; Fig. 2c, Supplementary Data 3).
Phosphorylated Ser residues were primarily located 5 amino
acids downstream of the SUMOylated residue, in agreement
with previously published observations on phosphorylation
dependent SUMOylation motif8. In contrast, no correlation
with respect to the SUMOylated Lys was found for
phosphorylated Thr residues.
Concomitant profiling of SUMOylation and ubiquitylation.
One of the main advantages of this method over other large-scale
approaches for SUMOylation site mapping is its compatibility
with the concomitant identification of ubiquitylation sites.
To show the feasibility of such an approach, we modified
our protocol to enrich ubiquitylated and SUMOylated peptides
on SUMOylated proteins (Fig. 3a). We opted to use this approach
to profile SUMOylation and ubiquitylation changes following
proteasome inhibition using MG132 for up to 8 h at 2 h intervals.
Western blot analysis of the total cell extract revealed an
overall increase of both SUMOylation and ubiquitylation levels
coupled with a B20% decrease in the pool of free SUMO or
ubiquitin (Supplementary Fig. 7). However, NiNTA enrichment
of SUMOylated proteins showed a significant enrichment
of both SUMOylated and ubiquitylated proteins with a high
degree of specificity in HEK293 cells expressing the SUMO3
mutant protein (Supplementary Fig. 7) whereas WT HEK293
cells did not show the corresponding enrichment (Supplementary
Fig. 8a). Moreover, we confirmed that the ubiquitylation signal
on our western blots did not arise only from ubiquitylation
on polySUMO chains by performing an in vitro deSUMOylation
assay (Supplementary Fig. 8b). Indeed, a portion of the ubiquitin
signal on the western blot appears to stem from ubiquitin
that is directly attached to the target substrate. We also assessed
the extent of nonspecific binders arising from the NiNTA
purification by comparing the number of identified SUMOylated
protein in our comprehensive analysis to the raw NiNTA extract
(Supplementary Fig. 8c). After NiNTA enrichment proteins
were digested with trypsin and ubiquitylated peptides were
enriched using the anti-K(GG) antibody cross linked to the
agarose beads to limit nonspecific binding to NiNTA beads32.
Since the occurrence of ubiquitylated peptides following NiNTA
purification is expected to be much lower than SUMOylated
peptides, we first performed immunoaffinity purification of
the Gly-Gly containing tryptic peptides to minimize sample
losses. Non-retained peptides found in the flow through
were then immunopurified using our optimized SUMO
enrichment protocol. Immunoprecipitated peptides eluted from
both purifications were injected separately using LC-MS/MS.
Supplementary Data 4 summarizes all SUMOylated and ubiqui-
tylated peptides identified in this study. In total, we identified
1,616 SUMOylation sites on 918 proteins and 349 ubiquitylation
sites on 194 proteins. Among the 349 ubiquitylated lysine
residues, only 221 were identified as uniquely ubiquitylated, while
128 were modified by both ubiquitin and SUMO. Interestingly,
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Figure 2 | Motif analysis of SUMO-modified lysine residues. (a) Pie chart distribution of identified SUMO3 sites based on sequence motif. SUMO3 sites
located within a full consensus sequence are represented in red, partial in blue, inverted in green and non-consensus in grey. (b) Distribution of the
identified SUMO motifs with regards to the intensity of their respective peptides. High abundance peptides are mostly represented by full consensus
sequences while low abundance peptides show partial or non-canonical consensus sequences. (c) Distribution of the phosphorylated residues with respect
to the SUMOylation sites identified on a peptide. (d) Phospho-dependent motif identified by Motif X using all the phosphorylated SUMOylated peptides.
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113 of the 194 ubiquitylated proteins were not identified as
SUMOylated. Since we performed an immunopurification
against K-(GG) containing peptides after the NiNTA
purification, we hypothesized that those unique proteins are
SUMOylated on the polyubiquitin motif. Indeed, our data
revealed more than 12 branched peptides on SUMO or
ubiquitin (Supplementary Fig. 9), which also explains the
concomitant SUMO/ubiquitin enrichment at the protein level.
While the function of such chains remains mostly unknown,
the ubiquitylation of polySUMOylation chains by the RING
Finger Protein 4 (RNF4) was associated with the recruitment
of ubiquitylated proteins for their subsequent proteasomal
degradation12. Since we used MG132 for these experiments
the RNF4-mediated degradation of these highly branched
products was abrogated, leading to their accumulation in the cell.
Next, we quantified sites only observed in consecutive
time points. This enabled the profiling of 778 SUMOylated
peptides and 124 ubiquitylated peptides, corresponding to
676 and 114 sites, respectively (Fig. 3b,d). While western blot
analysis reveals a global increase in the level of both SUMOyla-
tion and ubiquitylation (Supplementary Fig. 7), LC-MS/MS
analysis revealed that a small proportion of SUMOylation
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Figure 3 | Temporal profiling of the SUMOylome and ubiquitylome in response to MG132 treatment. (a) Overview of the strategy used to enrich
SUMOylated and ubiquitylated peptides. Peptides arising from the digestion of SUMOylated proteins were subjected to a first peptide IP using the
cross-linked anti-K-(GG) antibody. The flow through of the first IP was subjected to SUMOylated peptide enrichment with the anti-K-(NQTGG) antibody.
The two resulting eluates were injected separately on the LC-MS/MS setup. (b) Heat map of normalized intensity for SUMOylated peptides as a function
of MG132 treatment period. 1620 SUMO sites were identified with a localization confidence 40.75. Peptide identifications were clustered using
Fuzzy-C-means clustering. 676 sites were regulated and were divided in five groups based on their kinetic profiles. (c) Distribution of the proportion of
SUMO motifs over time. A depletion of both non-consensus and consensus motifs and an increase of non-canonical motif over the 8 h time period was
observed. (d) Heat map of normalized intensity for ubiquitylated peptides as a function of MG132 treatment period. 349 Ubi sites were identified with a
localization confidence 40.75. A total of 114 sites were regulated and were divided in 3 groups based on their kinetic profile.
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(6.4%) and ubiquitylation (8.0%) profiles were down regulated on
MG132 treatment. We also observed that the proportion
of SUMOylation sites in consensus motifs increased for the
first 2 h of the MG132 treatment and decreased then after at
the expense of mixed and inverted motifs (Fig. 3c). We surmised
that changes in the proportion of sequence motifs over time is
partly explained by promiscuous SUMOylation, and/or the
activation of SUMO E3 ligases brought on by extended exposure
to MG132, though we cannot exclude a possible influence
attributed to the use of SUMO3 mutation on the distribution
of SUMO motifs for extended periods of MG132 treatment.
Among all identified proteins, some are directly linked to
the regulation of UBLs. Indeed, we found that most of
the SUMOylation machinery (e.g. SAE1, UBA2, UBC9, PIAS1)
as well as some proteins from the ubiquitylation machinery
(e.g UBE2O, RNF40, TRIM32, USP22), are modulated by ubiqui-
tylation and/or SUMOylation. Moreover, 35% of all identified
proteins contained at least two modification sites, but only 5 of
these (UPS22, H2B, RDH11, HNRNPC and ZMYM4) showed
reciprocal effects, where the increase of a modification at one
site is accompanied with the simultaneous decrease at another
site on the same protein (Supplementary Fig. 10). Interestingly,
USP22 and its substrate H2B K121 (ref. 33) were among the
proteins that showed a reciprocal effect (Fig. 4). On MG132
treatment, we observed an increase in the SUMOylation of USP22
at K152 and ubiquitylation at K157. These changes were
accompanied by a decreased in the ubiquitylation of USP22
K417, a site located within its catalytic domain. In the case
of H2B, we observed a decrease of ubiquitylation that was
correlated with an increase of SUMOylation at K121. While the
ubiquitylation status of H2B is critical for the transcriptional
process34, the function of H2B SUMOylation is presently
unknown. Although USP22 is the only deubiquitinating enzyme
for which we saw a reciprocal effect, we noted a similar behaviour
for USP37 and its substrate c-Myc35 (Supplementary Fig. 11).
We observed an increase in the SUMOylation of USP37 at
K452 located in its catalytic domain, a change that was correlated
with an increase in the ubiquitylation of c-Myc at K148 and K389.
SUMOylation and ubiquitylation of ribosome and proteasome.
To better understand the connectivity between SUMOylated
and ubiquitylated proteins, we performed a string analysis
(Fig. 5). As expected, the network of SUMOylated proteins
shows a high degree of interconnectivity. Deeper exploration
of this network revealed several protein complexes, including
but not limited to the SWI-SNF complex (e.g. SMARCC1,
SMARCC2 and SMARCD2), the ribosome (e.g. RPLs, RPSs,
GNB2L) and the proteasome (e.g. PSMA, PSMB, PSM).
Ribosome biogenesis was previously shown to be a SUMO-
dependent mechanism36. We mapped all SUMOylation and
ubiquitylation sites identified on the ribosome to its crystal
structure (Supplementary Fig. 12a, PDB: 4UG0). In total,
we identified 447 SUMOylation sites and 26 ubiquitylation
sites on ribosomal proteins from kinetic and the 2DLC
experiments. All the quantified SUMOylation and ubiquity-
lation sites on the ribosome subunits were upregulated after
treatment with MG132. The structure highlights that the
modification sites are located at the interface between subunits
and possibly disrupt protein-protein and protein-RNA
interactions. Since SUMOylation is believed to generally occur
at a low stoichiometry (o5%), the effect of a single SUMOylation
event on ribosomal activity may be negligible37. However,
our kinetic studies have shown that 76 SUMO sites on
36 subunits are regulated by MG132. The compounded effect of
several SUMOylation events occurring simultaneously may
alter protein synthesis. This is consistent with the study
reported by Kadlcˇı´kova´ et al.38 which indicated that MG132
lead to a 10 to 20% decrease in protein synthesis.
The present study also highlighted that several proteasome
subunits were extensively modified. Data from both 2DLC
and kinetic experiments identified a total of 128 modified
lysine residues on proteasome subunits with several sites
showing a significant increase in their SUMOylation on MG132
treatment. We mapped all the modified lysine residues on the
recently available proteasome crystal structure (Supplementary
Fig. 12b, PDB: 4R3O). Among the 41 modified lysine residues,
36 are located at the surface of the 20S subunit while only
5 are observed inside the complex lumen (PSMA1 K115, PSMA2
K92, PSMA5 K91, PSMA6 K116 and PSMB3 K77). The
distribution of modified residues on the outer surface of the
proteasome subunits possibly implies that SUMOylation may
affect protein-protein interactions. We hypothesized that the
SUMOylation of the proteasome may act as an address tag
to direct its subcellular localization. To confirm this proposal,
we performed immunofluorescence analysis on 20S subunits in
cells treated or not treated with MG132 (Supplementary Fig. 13).
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These experiments indicated that the endogenous 20S core is
mainly cytoplasmic under untreated conditions, but is translo-
cated to the nucleus on MG132 treatment where it partially
co-localized with endogenous PML within the NBs (Supple-
mentary Fig. 13a). Similar observations were obtained when
these immunofluorescence experiments were performed with
the b regulatory subunit of the 11S (Supplementary Fig. 13b).
To investigate if the SUMO interacting motif (SIM) of PML is
required for the recruitment of SUMOylated proteasome to
PML NBs, we transfected HEK293-SUMO3m cells with PML IV
or PML IV-SIM that is mutated in its SIM core sequence
(VVVI hydrophobic amino acids; Fig. 6a). These experiments
revealed that the 20S proteasome subunits co-localized with
PML IV within the NBs in presence of MG132. In contrast,
cells transfected with PML IV-SIM failed to recruit the
proteasome under the same conditions (Fig. 6a). To confirm
these results, we performed the same experiments in PML /
murine embryonic fibroblast (MEF) cells co-transfected
with SUMO3 and PML IV or PML IV-SIM (Fig. 6c), which
again showed that the SIM of PML was required for
the recruitment of the 20S proteasome subunits to PML NBs.
These results also revealed that PML IV alone, in the absence
of the others isoforms, was able to recruit the proteasome
on MG132 treatment. The quantification of fluorescence
intensities in both HEK293-SUMO3m and PML / MEF cells
revealed that the portion of 20S associated to PML NBs
increased only in PML IV-expressing cells treated with MG132
(Fig. 6b,d). Indeed, Manders’ co-localization coefficient were
0.58 and 0.65 for PML IV in HEK293 SUMO3m cells
(Fig. 6b) and PML / MEFs (Fig. 6d) treated with MG132,
compared with 0.22 and 0.15 for PML IV-SIM in the same
cells, respectively.
While we cannot entirely rule out the possibility that other
modifications can affect the recruitment of the proteasome to
PML NBs, the observation that SUMOylation mediates its
recruitment is consistent with prior studies reporting
the co-localisation of the proteasome and PML under diffe-
rent cellular stress including arsenic trioxide (As2O3) (ref. 39).
Altogether, these data suggest that the SUMOylation of
the proteasome is a required signal for its recruitment via the
SIM of PML to PML NBs where it facilitates protein degradation
under different stress conditions.
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Discussion
The optimized SUMOylated peptide immunopurification
protocol provides an efficient approach to obtain unambiguous
identification of SUMOylation sites on protein substrates.
Altogether, this approach enabled the proteome-wide identifica-
tion of 10,388 SUMO sites on 3,556 proteins in HEK293
cells. Approximately half of these sites were also identified in
recent large-scale SUMO proteome analyses that used different
cell lines and stimuli. Interestingly, SUMO consensus motifs were
largely represented by highly abundant SUMOylated peptides
while non-consensus motifs were mostly found for low
abundance peptides, possibly highlighting promiscuous SUMOy-
lation and/or the activation of SUMO E3 ligases taking place over
extended periods of proteasome inhibition.
This method can be advantageously combined with immu-
noaffinity enrichment of ubiquitylated peptides to determine
the extent of crosstalk between these modifications, and
rationalize their functional relationships. For example, protein
SUMOylation can mediate the recruitment of E3 ubiquitin
ligases, which catalyse the ubiquitylation and proteasomal
degradation of protein substrates1. A case in point is the ubiqu-
itin ligase RNF4 that contains multiple SIMs and recognizes
poly-SUMOylated proteins for their targeted proteasome
degradation. RNF4 also associates with PML NBs under
As2O3 treatment and proteasome inhibition39–42. Recently,
additional polySUMO-binding proteins, including Arkadia,
FLASH, C5orf25 and SOBP, have been identified through
a computational string search43. As such, it is becoming
clear that the PML/SUMO/poly-SUMO-dependent ubiquitin
E3 ligases/proteasome complex constitutes a general mechanism
to destroy NB-targeted proteins. While PML NBs are known
to be a site of protein degradation, the exact mechanism by
which proteasomes are recruited to these nuclear structures is
not entirely known. Using a quantitative proteomics approach,
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we uncovered that several proteasome subunits are SUMOylated
on MG132 treatment, and that this modification is required
for the recruitment of the proteasome to PML NBs via the
SIM of PML. Accordingly, PML lacking the SIM sequence
is resistant to As2O3-induced PML degradation due to its inability
to recruit the proteasome components in PML NBs39. It is
noteworthy that previous reports highlighted the co-localization
of the proteasome with lytic vesicles such as autophagosomes44,
phagosomes45 and exosomes46 when cells are exposed to different
stimuli. Proteasome SUMOylation could thus provide a conve-
nient recognition signal to recruit the degradation machinery
at primary sites of ubiquitin-mediated proteolysis.
The dynamic profiling of protein SUMOylation and ubiquity-
lation also revealed unexpected crosstalk between UBL modifiers.
Moreover, we observed that USP22 and USP37 can be modified
by SUMO and ubiquitin at various sites simultaneously and
are regulated by MG132, though their functions remain to
be identified. Deubiquitylation of USP22 at K417, a site located
within its catalytic domain, led to the decreased ubiquitylation
of H2B at K121 and its subsequent SUMOylation. Similarly,
the increased SUMOylation of USP37 at its catalytic site
K452 correlated with an increase in ubiquitylation of its substrate
c-Myc at K148 and K389. These observations suggest that
the SUMOylation or ubiquitylation of lysine residues within
the catalytic domain of deubiquitinating enzymes could represent
a novel inhibitory mechanism mediating their enzymatic
activities.
These results demonstrate that immunoaffinity methods
enabling the enrichment of SUMOylated and ubiquitylated
peptides can be used to isolate UBL-modified substrate
lysine residues present at low abundance in human cells.
This approach opens up new avenues for the identification of
protein substrates, their site-specific modifications, the interplay
between SUMOylation and ubiquitylation, and their regulation
on different environmental conditions.
Methods
Materials. SCX spin tips (SP-155) were purchased from Protea
(Morgantown, WV). PureProteome Protein A/G Mix Magnetic Beads
(LSKMAGAG10) was purchased from EMD Millipore (Ottawa, ON, Canada).
Dimethyl pimelimidate (DMP) cross-linking reagent (21,666) was obtained from
ThermoFisher scientific (Burlington, ON, Canada). The custom anti-K(NQTGG)
SUMO remnant antibody was obtained from Epitomics/Abcam (Burlingame, CA).
PTMScan Ubiquitin Remnant Motif (K-e-GG) Kit (5,562) was purchased from
Cell Signalling Technologies (Danvers, MA). Modified porcine sequencing grade
modified Trypsin was obtained from Promega (Madison, WI, USA).
Acetonitrile was purchased from Fisher Scientific (Whitby, ON, Canada).
Ammonium bicarbonate and formic acid were obtained from EM Science
(Mississauga, ON, Canada). 2-mercaptoethanol, ammonium hydroxide,
trifluoroacetic acid, 2- chloroacetamide, protease inhibitor cocktail
(4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatinA, E-64, bestatin, leupeptin
and aprotinin), phosphatase inhibitor cocktail (sodium vanadate, sodium
molybdate, sodium tartrate and imidazole) were purchased from Sigma-Aldrich
(Oakville, ON, Canada). Bradford protein reagent was obtained from Bio-Rad
(Mississauga, ON, Canada). Tris base was purchased from EMD Omnipur
(Lawrence, KS). PBS was obtained from HyClone (Thermo Scientific, Logan, UT).
Oasis hydrophilic-lipophilic balance (HLB) cartridges (1cc, 30mg) were purchased
from Waters (Milford, MA). ECL chemiluminescence detection system was pur-
chased from Amersham Pharmacia Biotech (Montre´al, QC, Canada). Mouse anti-
PML (sc-966) was obtained from Santa Cruz. Rabbit anti-proteasome activator
11Sb (BML-PW8240) and anti-20 S (BML-PW8155) antibodies were purchased
from Enzo life sciences (Brockville, ON, Canada). Goat anti-mouse IgG and goat
anti-rabbit IgG secondary antibodies were purchased from Millipore (Ottawa, ON,
Canada). Solvents for chromatographic analysis were all high-performance liquid
chromatography (HPLC) grade (Fisher Scientific and in-house Milli-Q water).
Capillary HPLC columns for nano-LC-MS were packed in-house using Jupiter C18
(3mm) particles from Phenomenex (Torrance, CA), and fused silica tubing from
Polymicro Technologies (Phoenix, AZ). PML IV (accession number NP_002666.1)
was used in this study. PML IV-SIM mutant was obtained by mutating the four
hydrophobic residues from the SIM (VVVI) to (AAAS). Cell viability was evaluated
using the Cell Proliferation Kit I (MTT) purchased from Roche (Mississauga, ON,
Canada).
Cell culture. HEK293 stably expressing 6xHisSUMO-3-Q87R-Q88N cells
(SUMO3m) were obtained by transfecting HEK293 cells with our SUMOm gene in
pcDNA3 and subsequent neomycin selection (0.5mgml 1)16. MEFs
PML  / were derived from PML knock out mice47. Cells were grown in
DMEM supplemented with 10% FBS, 1% L-Glu, 1% penicillin/streptomycin
and 750 mgml 1 geneticin at 37 C in a 5% CO2 atmosphere. At 70% confluence,
cells were either mock treated or treated with 10 mM MG132 for up to 16 h. For
the kinetic profiling, a single T175 flask has been used per time point.
Protein purification and digestion. HEK293 SUMO3m cells were washed
twice with ice cold PBS and lysed in NiNTA denaturing incubation buffer
(6 M Guanidinium HCl, 100mM NaH2PO4, 10mM Tris-HCl, 20mM
2-Chloroacetamide, 5mM 2-Mercaptoethanol, pH¼ 8) and sonicated. Total
protein content was determined using micro Bradford assay. For each condition,
4mg of total cell extract (TCE) were incubated with 80 mL of NiNTA beads for 16 h
at 4 C. NiNTA beads were washed once with 1mL of NiNTA denaturing incu-
bation buffer, 5 times with 1mL of NiNTA denaturing washing buffer (8 M urea,
100mM NaH2PO4, 10mM Tris-HCl, 20mM imidazole, 5mM 2-Mercaptoethanol,
20mM Chloroacetamide, pH¼ 6.3) and finally twice with 1mL of 100mM
ammonium bicarbonate. The protein content was determined by micro Bradford
assay. On beads protein digestion was performed by adding trypsin to a ratio
1:50 by weight (Trypsin:Protein extract) for 4 h at 37 C. Resulting NiNTA
enriched digests were acidified by adding trifluoroacetic acid to a final
concentration of 1%, desalted on HLB cartridges as per manufacturer’s instructions
and eluted in LoBind tubes before being dried down by Speed Vac.
Antibody cross-linking. PureProteome protein A/G magnetic beads were
equilibrated with anti-K(NQTGG) antibody (2 mg of antibody per ml of slurry)
for 1 h at 4 C in PBS. Saturated beads were washed 3 times with 200mM
triethanolamide pH¼ 8.3. For crosslinking, 10 ml of 5mM DMP in 200mM
triethanolamide pH¼ 8.3 was added per ml of slurry and incubated 1 h at
room temperature. The reaction was quenched for 30minutes by adding
5% (v/v) of 1 M Tris-HCl pH¼ 8. Cross-linked beads were washed 3 times with
ice cold PBS and once with PBS containing 50% Glycerol and stored at
 20 C for future use.
Dual peptide IP. For the ubiquitin IP, dried digests were reconstituted in 500 mL of
PBS and supplemented with 31 mg of anti-K(GG) antibody. The flow through
was kept for the anti-K(NQTGG) IP. Anti-K(GG) antibody bound beads were
washed three times with PBS. Ubiquitylated peptides were eluted 3 times with
200 mL of 0.2% formic acid in water and filtered through a 0.45 mm spin tube.
Eluted peptides were dried down by speed vac and stored at  80 C for MS
analysis. For the anti-K-(NQTGG) IP, ubiquitin IP flow throughs were diluted
with 90% Glycerol in PBS to obtain a final glycerol concentration of 50%,
supplemented with 20 mg of cross-linked anti-K-(NQTGG) (1:2 by weight
(Antibody:NiNTA digest)) and incubated for 1 h at 4 C. anti-K-(NQTGG)
antibody bound beads were washed three times with 1ml of 1 PBS, twice
with 1ml of 0.1X PBS and once with water. SUMO peptides were eluted
4 times with 100 ml of 0.2% formic acid in water and filtered through a 0.45 mm
spin tube. Eluted peptides were dried down by speed vac and stored at  80 C for
MS analysis.
SCX fractionation. Peptides were reconstituted in water containing
15% acetonitrile and 0.2% formic acid and loaded on conditioned Protea SCX tips.
Peptides were eluted with ammonium formate pulses at 50, 75, 100, 300, 600 and
1,500mM in 15% acetonitrile, pH¼ 3 (pH adjusted with formic acid). Salts
factions were dried down by speed vac.
Mass spectrometry analysis. Peptides were reconstituted in water containing
0.2% formic acid and analysed by nanoflow-LC-MS/MS using an Orbitrap Fusion
Mass spectrometer (Thermo Scientific) coupled to a Proxeon Easy-nLC 1000.
Samples were injected on a 300 mm ID 5mm trap and separated on a
150 mm 20 cm nano LC column (Jupiter C18, 3 mm, 300A, Phenomenex).
The separation was performed on a linear gradient from 7 to 30% acetonitrile,
0.2% formic acid over 105minutes at 600 nl per min. Full MS scans were acquired
from m/z 350 to m/z 1,500 at resolution 120,000 at m/z 200, with a target
AGC of 1E6 and a maximum injection time of 200ms. MS/MS scans were acquired
in HCD mode with a normalized collision energy of 25 and resolution 30,000
using a Top 3 s method, with a target AGC of 5E3 and a maximum injection
time of 3,000ms. The MS/MS triggering threshold was set at 1E5 and the
dynamic exclusion of previously acquired precursor was enabled for 20 s within
a mass range of ±0.8Da.
Data processing. Peptide identification was performed using MaxQuant
(version 1.5.1.2)48. MS/MS spectra were searched against Uniprot/SwissProt
database including Isoforms (released on 10 March 2015). The maximum
missed cleavage sites for trypsin was set to 2. Carbamydomethylation (C) was
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set as fixed modification and acetylation (Protein N term), phosphorylation (STY),
oxidation (M), deamination (NQ), GG (K) and NQTGG (K) were set as variable
modifications. The false discovery rate for peptide, protein, and site identification
was 1%. SUMO sites with a localization probability of 40.75 were retained.
Peptide quantification was achieved with match between runs enabled. To regroup
identified site according to their kinetic profiles, Fuzzy-C-means algorithm49
platform developed in our lab50 was used. Briefly, data processing was performed
in an R environment (www.r-project.org) with the MFuzz package51. Sites that
were not detected in at least 3 time point or that were detected in non-contiguous
time points were automatically rejected. Sites with a membership value higher
than 0.5 were retained for downstream analysis. Pearson coefficients for biological
reproducibility were obtained by plotting the fold changes of MG132/control
for the three biological replicates.
Bioinformatics analysis. Sequence windows spanning ±6 amino acids around
the modified lysine residue obtained in Andromeda were submitted to
Motif X (ref. 30). For peptide sequences corresponding to multiple proteins,
only the leading sequence was submitted. Network analysis was done
using String database52 with highest confidence (score40.9) and experimental
data only.
Fluorescence imaging and co-localization analysis. Cells grown on glass
coverslip were fixed with cold acetone for 10min at  20 C. Cells were prepared
for immunofluorescence staining and analysed by confocal microscopy. PML was
detected with mouse anti-PML (sc-966) antibody and the corresponding
anti-IgG antibody conjugated to Alexa 594. The rabbit polyclonal antibodies
against proteasome 20 S core and against regulatory subunit of 11 S b were used
for detection of proteasome components followed by Alexa 488. The cells
were washed in PBS, stained with 4,6-diamidino-2-phenylindole and mounted
in Fluoromount-G medium. Images were digitally acquired with a Zeiss
LSM 710 confocal Microscope. For quantification of 20 S co-localization with
PML IV or PML IV-SIM on MG132 treatment, the JACoP plugin in ImageJ
software53 was used and the Manders’ coefficient was calculated, n¼ 60 cells
per condition.
Western blot. An aliquot of 10 mg TCE prepared in NiNTA denaturing incubation
buffer were diluted in Laemmli buffer (10% (w/v) glycerol, 2% SDS, 10% (v/v)
2-mercaptoethanol and 0.0625M Tris-HCl, pH¼ 6.8), boiled for 10min and
separated on a 4–12% SDS-PAGE followed by transfer onto nitrocellulose
membranes. For NiNTA purified material, 100 mg of TCE from WT cells
or 10 mg of TCE from SUMO3m cells were purified as indicated before on NiNTA
beads, eluted in Laemmli buffer and boiled for 10minutes before SDS-PAGE.
Before blocking the membrane for 1 h with 5% non-fat milk in TBST (tris-buffered
saline with Tween 20), membranes were briefly stained with 0.1% Ponceau-S in 5%
acetic acid to represent total protein content. Membranes were subsequently
probed with the primary antibody, as indicated, in blocking solution at 4 C for
16 h. (SUMO2/3, 1:2,000, Zymed; Ubiquitin, 1:200, Santa Cruz; Histone H3,
1:1,000, Cell Signalling Technologies) The membranes were incubated with sec-
ondary antibodies (goat anti-rabbit HRP, EMD Millipore, 1:5,000 and goat anti-
mouse HRP, EMD Millipore, 1:5,000) for 1 h at room temperature. Membranes
were washed three times with TBST for 10minutes each. Membranes were revealed
using ECL (GE healthcare) as per the manufacturer’s instructions, and chemilu-
minescence was captured on Blue Ray film.
Data availability. The raw data that support the findings of this study are available
from Peptide Atlas, http://www.peptideatlas.org with the accession code
PASS00896. The additional data that support the findings of this study are available
from the corresponding author on request.
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